Moximed, Inc. is dedicated to improving the standard of care for patients with osteoarthritis (OA). OA, the most common form of arthritis, leads to a breakdown of the joint’s cartilage and often results in joint pain and loss of motion.
Moximed was founded on the principles of joint unloading and is currently focused on providing a joint preserving option that will allow patients with knee OA to live the highly active lives that they expect and deserve. Joint unloading is a proven therapy that has recently become more prominent as the need for cost-effective pre-arthroplasty (pre-joint replacement) solutions becomes more evident.
The company has raised over $100MM from world-leading investors and currently has 20 issued US patents and over 120 pending or issued patents worldwide.